Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 9539340

    Bladder cancer specific ligand peptides

    The Regents of the University of California · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9540641

    Cancer treatment

    Ionis Pharmaceuticals, Inc. · Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9534033

    Targeted interferons demonstrating potent apoptotic and anti-tumor activities

    The Regents of the University of California · Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9527919

    High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection

    The Regents of the University of California · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9523691

    Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis

    INSTITUT DE CANCEROLOGIE DE L'OUEST · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9522185

    Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9522955

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9522910

    Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU “FUSION PHARMA” · Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9517229

    Treatment of breast cancer

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9517243

    Beta-mannosylceramide and stimulation of NKT cell anti-tumor immunity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9517240

    Methods and compositions for cancer prevention and treatment

    The Regents of the University of California · Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9512138

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9506926

    Molecular predictors of therapeutic response to specific anti-cancer agents

    The Regents of the University of California · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9504745

    Compositions and methods for cancer treatment using targeted carbon nanotubes

    The Board of Regents of the University of Oklahoma · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9493552

    Therapeutic biologic for treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9492564

    Dual specific immunotoxin for brain tumor therapy

    The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9492538

    Isolation and use of solid tumor stem cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9487575

    Compositions and methods for treatment of gynecologic cancers

    The Regents of the University of California · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9487556

    Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9481662

    Seriniquinones, melanoma-specific anticancer agents

    The Regents of the University of California · Granted Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9480725

    Fermented wheat germ proteins (FWGP) for the treatment of cancer

    The Regents of the University of California · Granted Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9480754

    Phospholipid ether analogs as cancer-targeting drug vehicles

    CELLECTAR BIOSCIENCES, INC. · Granted Tue Nov 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9475871

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9468632

    Methods and compositions for targeting cancer stem cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9469879

    Lymphoma prognostic methods and kits

    Regents of the University of Minnesota · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9469878

    Methods of treating cancer comprising targeting NQO1

    The Board of Regents of the University of Texas System · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9470689

    N-cadherin: target for cancer diagnosis and therapy

    The Regents of the University of California · Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9458095

    Oligo-benzamide compounds and their use in treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9452182

    Collateral gene inactivation biomarkers and targets for cancer therapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9446048

    Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9447144

    MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9447419

    RNAi-mediated inhibition of tumor necrosis factor α-related conditions

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9433686

    Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function

    The Regents of the University of California · Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9416190

    Mesothelin antibodies and methods for eliciting potent antitumor activity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9415098

    DNA vaccine for use in pancreatic cancer patients

    Vaximm AG · Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. EP 3053920

    VERBINDUNGEN MIT ANTITUMORAKTIVITÄT

    AB SCIENCE [FR] · Granted Wed Aug 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Aug 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9409965

    Kidney-specific tumor vaccine directed against kidney tumor antigen G-250

    The Regents of the University of California · Granted Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9409990

    Methods of inhibiting tumor growth by antagonizing IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9402820

    Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9403800

    Compounds for inhibition of cancer cell proliferation

    ChemRegen, Inc. · Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9403911

    Compositions and methods for detection and treatment of cancer

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9394359

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9394358

    Gene signature for predicting prognosis of patients with solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9394569

    Methods and kits for early detection of cancer or predisposition thereto

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jul 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9388247

    Antibodies against cancer target block tumor growth, angiogenesis and metastatis

    The Regents of the University of California · Granted Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 2016185873

    MONOCLONAL ANTIBODIES FOR TREATMENT OF CANCER

    GANYMED PHARMACEUTICALS AG [DE] · Granted Thu Jun 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9375474

    Compounds useful for inhibiting metastasis from cancer and methods using same

    Alliance Discovery, Inc. · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9375475

    Combination immunotherapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.